Skip to main content
. Author manuscript; available in PMC: 2014 Jun 1.
Published in final edited form as: Ther Drug Monit. 2013 Jun;35(3):332–337. doi: 10.1097/FTD.0b013e318286dd3f

Figure 3.

Figure 3

Observed sirolimus concentrations (n=545) as part of the PK guided dosing in 44 patients with NF1 during the two-year trial period. Note: actual measured concentrations frequently were below the 10 ng/mL target as the time after the last dose often exceeded 12 hours or because of missed doses.

HHS Vulnerability Disclosure